Biogen said on Tuesday that it might exchange its chief govt and successfully hand over on advertising a high-profile Alzheimer’s drug that has been a business failure since its controversial approval practically a 12 months in the past.
Michel Vounatsos, who has led the drug maker for over 5 years and presided over the approval and launch of the drug, often known as Aduhelm, will stay in his function till a successor is appointed, Biogen mentioned.
Biogen mentioned it deliberate to “considerably eradicate” its spending on the drug after Medicare formally determined final month to sharply restrict its protection of Aduhelm.
The Meals and Drug Administration accredited Aduhelm in June. It was the primary new remedy for Alzheimer’s in practically 20 years. It had been extensively anticipated to turn out to be a blockbuster drug inside a number of years, producing billions of {dollars} yearly for Biogen. However the approval was overshadowed by concern in regards to the drug’s unproven advantages and severe security dangers, in addition to in regards to the course of by which the F.D.A. had greenlighted it.
Docs, insurers, and sufferers and their households haven’t embraced Aduhelm. On Tuesday, Biogen reported that the drug had introduced in simply $2.8 million in income within the first three months of this 12 months, after producing solely $3 million in 2021. Biogen initially priced the drug at $56,000 per 12 months for the common affected person earlier than halving the price in response to weak early gross sales.
Aduhelm had been anticipated to pressure authorities well being budgets. However Medicare determined to pay for the drug just for individuals who obtain it as members in a scientific trial. Final month, Biogen mentioned it might withdraw its application to market the drug within the European Union after drug reviewers indicated that it was unlikely to win approval.
